CTRI/2021/12/038357已完成4 期
A Post-marketing Clinical Investigation Study to assess safety and efficacy of Hydrozid Spray for cryotherapy in superficial epidermal and dermal lesions.
BIBAWO Medical Private Limited0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patientsof age between 18 to 65 years both inclusive.
- •2. Patient has atleast one or more epidermal or dermal skin lesions (e.g., Verruca plantaris, Verruca vulgaris, Verruca plana, Keratosis seborrhoica, Lentigo (facial), Lentigo (non-facial), Acrochordon (skin tag),), Keratosis actinica (facial), Keratosis actinica (non-facial) Molluscum contagiosum )lesions of diameter bÃ?ªtween ââ?°Â¥ 5 mm and ââ?°Â¤ 10 mm in an area suitable for treatment.
- •3. Patient is willing to have digital photographs taken of the treatment area and agrees to use ofphotographs for presentation, educational, or marketing purposes.
- •4. Patients who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
排除标准
- •1. Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin colour, in the area of intended treatment in the previous 1 month (e.g., hydroquinone, corticosteroids, laser surgery)
- •2. Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period
- •3. Open wounds, cuts and delicate or eczematous skin,Scars or tattoos in the location of the treatment sites
- •4. History of melanoma.
- •5. Known history of illness or adverse reaction to cold insult (e.g..cryoglobulinaemia, Raynaudââ?¬•s disease, cold urticaria, blood dyscrasias, or uncertain diagnosis).
- •6. Patients who have impaired healing eg due to diabetes, vascular disease, vitamin A deficiency, hyperthyroidism and hypothyroidism.
- •7. Patients who took immunosuppressant drugs such as oral corticosteroids within the past three months.
- •8. Patients who have autoimmune diseases, eg SLE, dermatomyositis, scleroderma and other diseases.
- •9. Patient has a history of sensitivity to any of the ingredients in the study medications.
- •10. Patients who cannot tolerate cryotherapy for their own reasons.
- •11. Patient has any current skin disease (e.g., Psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator,might put the Patient at undue risk by study participation or interfere with the study conduct or
- •evaluations.
- •12. Inability or unwillingness to comply with the study requirements.
- •13. Female Patients who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study.
- •14. History of alcohol abuse and smoking.
- •15. Current enrollment in a clinical study of any other unapproved investigational drug or device within 30 days prior to signing informed consent.
研究者
相似试验
已完成
4 期
Tibia bone related fracture fixation studyCTRI/2022/10/046936Kaulmed Pvt. Ltd.
已完成
不适用
A Post-Market Clinical Follow-up Study to Investigate the Usability of the CollaGUARD Adhesion Barrier following Hysteroscopic AdhesiolysisNL-OMON41131Innocoll Technologies10
招募中
不适用
A post market clinical follow-up study with the aneXys ceramys inlay DEM16.7M16.1Other secondary coxarthrosisOther primary coxarthrosisDRKS00018809Mathys Orthopädie GmbH150
已完成
不适用
A post market clinical follow-up study with the aneXys acetabular cup and ceramys inlayM16.1M16.7Other primary coxarthrosisOther secondary coxarthrosisDRKS00021508Mathys AG Bettlach150
已完成
不适用
Post-market clinical follow-up study evaluating the efficacy and safety of the wearable cardioverter-defibrillator (WCD) medical device 'LifeVest' in real-life settings in FranceISRCTN91372291ZO550